Structural Allograft as an Option for Treating Infected Hip Arthroplasty with Massive Bone LossLee, Paul, T. H., MB BCh, MA, FRCS (Eng), FRCS (Tr & Orth)1; Clayton, Robert, A., MBBS, FRCS (Edin), FRCS (Tr & Orth)1; Safir, Oleg, A., MD, FRCSC, MEd1; Backstein, David, J., MD, FRCSC, MEd1; Gross, Allan, E., MD, FRCSC, OOnt1, a
Background Revision of the infected hip arthroplasty with major bone loss is difficult. Attempts to restore bone stock with structural allograft are controversial.
Questions/purposes We assessed the (1) reinfection rate; (2) rerevision rate; (3) radiographic graft union, resorption, and implant migration; (4) Harris hip scores at 1 year and at last followup compared with before surgery; and (5) other major complications associated with the use of bulk structural allograft to treat massive bone loss in infected hip arthroplasty.
Methods We retrospectively reviewed 27 patients who underwent two-stage revision arthroplasty using structural allograft to treat massive bone defects in infected hip arthroplasty. There were 17 proximal femoral grafts, three acetabular major column grafts, two acetabular minor column grafts, and 10 cortical strut grafts used. Five patients had combinations of two allografts. The minimum followup was 1.1 years (mean, 8.2 years; range, 1.1-16.8 years).
Results One of 27 patients had reinfection. The Kaplan-Meier survivorship was 93% at 10 years with rerevision for aseptic loosening as the end point. Radiographically, three patients had nonunion at the graft-host junction. All patients except two had graft resorption, of which all were mild except two, which were severe. Three patients had implant migration. The mean modified Harris hip scores were 39.2 points (range, 25-60) preoperatively, 67.3 points (range, 40-91) at 1-year followup, and 70.3 points (range, 46-81) at last followup. Other major complications included one patient with dislocation and one patient with transient sciatic nerve injury.
Conclusions Based on our data, we believe the use of structural allografts is a reasonable option for treating massive bone loss in infected hip arthroplasties.
Level of Evidence Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.